Trial Profile
An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2018
Price :
$35
*
At a glance
- Drugs Tavaborole (Primary)
- Indications Onychomycosis
- Focus Therapeutic Use
- Sponsors Pfizer
- 20 May 2014 New trial record